| Underrepresentation of patients 65 years of age or older in cancer-treatment trials LF Hutchins, JM Unger, JJ Crowley, CA Coltman Jr, KS Albain New England Journal of Medicine 341 (27), 2061-2067, 1999 | 2572 | 1999 |
| Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ... New England Journal of Medicine 372 (10), 923-932, 2015 | 663 | 2015 |
| Role of clinical trial participation in cancer research: barriers, evidence, and strategies JM Unger, E Cook, E Tai, A Bleyer American Society of Clinical Oncology educational book. American Society of …, 2016 | 563 | 2016 |
| Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group KS Albain, JM Unger, JJ Crowley, CA Coltman, DL Hershman JNCI: Journal of the National Cancer Institute 101 (14), 984-992, 2009 | 496 | 2009 |
| Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma PJ Stiff, JM Unger, JR Cook, LS Constine, S Couban, DA Stewart, ... New England Journal of Medicine 369 (18), 1681-1690, 2013 | 482* | 2013 |
| New treatment options have changed the survival of patients with follicular lymphoma RI Fisher, M LeBlanc, OW Press, DG Maloney, JM Unger, TP Miller Journal of Clinical Oncology 23 (33), 8447-8452, 2005 | 482 | 2005 |
| Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018 JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ... JAMA oncology 5 (10), e191870-e191870, 2019 | 429 | 2019 |
| Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation JM Unger, R Vaidya, DL Hershman, LM Minasian, ME Fleury JNCI: Journal of the National Cancer Institute 111 (3), 245-255, 2019 | 427 | 2019 |
| Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other … LM Rimsza, RA Roberts, TP Miller, JM Unger, M LeBlanc, RM Braziel, ... Blood 103 (11), 4251-4258, 2004 | 387 | 2004 |
| Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study … DO Persky, JM Unger, CM Spier, B Stea, M LeBlanc, MJ McCarty, ... Journal of clinical oncology 26 (14), 2258-2263, 2008 | 358 | 2008 |
| Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic … M Lambertini, HCF Moore, RCF Leonard, S Loibl, P Munster, M Bruzzone, ... Journal of clinical oncology 36 (19), 1981-1990, 2018 | 354 | 2018 |
| Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, ... JAMA oncology 2 (4), 453-461, 2016 | 318* | 2016 |
| Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial DL Hershman, JM Unger, H Greenlee, JL Capodice, DL Lew, AK Darke, ... Jama 320 (2), 167-176, 2018 | 297 | 2018 |
| Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of … OW Press, JM Unger, RM Braziel, DG Maloney, TP Miller, M LeBlanc, ... Journal of Clinical Oncology 24 (25), 4143-4149, 2006 | 289 | 2006 |
| Patient income level and cancer clinical trial participation JM Unger, DL Hershman, KS Albain, CM Moinpour, JA Petersen, K Burg, ... Journal of Clinical Oncology 31 (5), 536-542, 2013 | 275 | 2013 |
| Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group SH Bernstein, JM Unger, M LeBlanc, J Friedberg, TP Miller, RI Fisher Journal of clinical oncology 27 (1), 114-119, 2009 | 267 | 2009 |
| Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest … VK Sondak, PY Liu, RJ Tuthill, RA Kempf, JM Unger, JA Sosman, ... Journal of clinical oncology 20 (8), 2058-2066, 2002 | 256 | 2002 |
| Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy DL Hershman, JM Unger, KD Crew, LM Minasian, D Awad, CM Moinpour, ... Journal of Clinical Oncology 31 (20), 2627-2633, 2013 | 242 | 2013 |
| Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome JA Sosman, JM Unger, PY Liu, LE Flaherty, MS Park, RA Kempf, ... Journal of Clinical Oncology 20 (8), 2067-2075, 2002 | 233 | 2002 |
| Comparison of survival outcomes among cancer patients treated in and out of clinical trials JM Unger, WE Barlow, DP Martin, SD Ramsey, M LeBlanc, R Etzioni, ... Journal of the National Cancer Institute 106 (3), dju002, 2014 | 224 | 2014 |